Astrazeneca plc ADR (NASDAQ: AZN): The Best-Of-Breed For Investing?

Currently, there are 3.10B common shares owned by the public and among those 3.10B shares have been available to trade.

The company’s stock has a 5-day price change of 1.73% and -0.52% over the past three months. AZN shares are trading -0.52% year to date (YTD), with the 12-month market performance down to -3.18% lower. It has a 12-month low price of $60.47 and touched a high of $76.56 over the same period. AZN has an average intraday trading volume of 6.28 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.84%, 1.96%, and 0.18% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Astrazeneca plc ADR (NASDAQ: AZN) shares accounts for 15.98% of the company’s 3.10B shares outstanding.

It has a market capitalization of $207.73B and a beta (3y monthly) value of 0.53. The stock’s trailing 12-month PE ratio is 35.11, while the earnings-per-share (ttm) stands at $1.91. The company has a PEG of 2.68 and a Quick Ratio of 0.64 with the debt-to-equity ratio at 0.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.34% over the week and 1.17% over the month.

Analysts forecast that Astrazeneca plc ADR (AZN) will achieve an EPS of $1.25 for the current quarter, $1.35 for the next quarter and $4.38 for 2025. The lowest estimate earnings-per-share for the quarter is $0.89 while analysts give the company a high EPS estimate of $1.92. Comparatively, EPS for the current quarter was $0.96 a year ago. Earnings per share for the fiscal year are expected to increase by 11.70%, and 12.93% over the next financial year. EPS should shrink at an annualized rate of 13.10% over the next five years, compared to 17.72% over the past 5-year period.

Morgan Stanley coverage for the Astrazeneca plc ADR (AZN) stock in a research note released on January 23, 2024 offered a Overweight rating with a price target of $85. UBS was of a view on January 16, 2024 that the stock is Sell, while Jefferies gave the stock Hold rating on January 03, 2024, issuing a price target of $78.50- $70. HSBC Securities on their part issued Buy rating on December 18, 2023.

Most Popular

Related Posts